相关实验视频

Updated: Mar 22, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

人性化抗IL-5抗体治疗

Marc E Rothenberg¹

¹Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA.

|April 23, 2016

概括

针对INTERLEUQIN-5 (IL-5) 的新药有效抑制乙氨基. 人性化的抗IL-5抗体为严重的酸性喘提供了一种新疗法,标志着喘治疗的重大进步.

科学领域:

免疫学
肺病学
药理学

背景情况:

乙酸在严重的乙酸性喘中起着关键作用.
干白素-5 (IL-5) 是一种关键的细胞因子,对乙酸细胞的发育和功能起到关键作用.
现有的喘治疗方法不能充分解决严重的酸性表型.

研究的目的:

评估一种针对IL-5的新类药物的疗效.
评估人性化抗IL-5抗体对氨酸细胞抑制的影响.
确定抗IL-5疗法的治疗潜力.

主要方法:

给患有严重酸性喘的患者提供人性化的抗IL-5抗体.
在血液和唾液中监测乙素水平.
对喘症状控制和恶化率的评估.

主要成果:

在接受抗IL-5抗体治疗的患者中观察到显著的氨基酸抑制.
抗IL-5抗体在治疗严重酸性喘方面表现出有效性.
这是12年来首次获得批准的新型喘药物.

结论:

用人性化抗体向IL-5是一种有前途的治疗策略.
这种方法为患有严重酸性喘的患者提供了新的治疗选择.
进一步的研究可能会探索IL-5抑制在呼吸系统疾病中的更广泛应用.

更多相关视频

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery

Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery

Published on: September 27, 2021

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...